| Abstract |
Objective To investigate the effects of metformin on metabolic disorders in patients with schizophrenia caused by risperidone. Methods 128 patients with schizophrenia caused by oral risperidone were randomly divided into a study group (64 cases) and a control group (64 cases). Both groups were given behavioral intervention. The study group was treated with metformin (1.5 g / d). The body weight and related biochemical and immune indexes were measured before treatment and 16 weeks after treatment for comparison. Results After treatment, the FBG, 2hPBG, 2hPINS, HOMA-IR, BMI, TC, TG, and LDL-C in the study group were significantly lower than before treatment (P <0.01, P <0.001). HOMA-IR and BMI were significantly lower than before treatment, and the differences were statistically significant (P <0.05, P <0.001). After treatment, the FBG, 2hPBG, 2hPINS, HOMA-IR, BMI, TC, TG, and LDL-C in the study group were significantly lower than those in the control group, and the differences were statistically significant (P <0.01, P <0.001). There was no significant difference in the incidence of adverse reactions between the study group (9.84%) and the control group (6.45%) (χ2= 0.127, P> 0.05), and both were tolerable. Conclusion Metformin combined with behavioral intervention can significantly improve the weight gain and abnormal glucose and lipid metabolism in patients with schizophrenia caused by risperidone. There are no obvious adverse reactions in the short term, which is worthy of clinical promotion.
|